Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(7):897–902. doi: 10.1054/bjoc.2001.1703

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women

M B Marttunen 1, B Cacciatore 1, P Hietanen 2, S Pyrhönen 2, A Tiitinen 1, T Wahlström 3, O Ylikorkala 1
PMCID: PMC2363827  PMID: 11286468

Abstract

To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II–III breast cancer. Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment. In a subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12 months of treatment. The mean (±SD) follow-up time was 2.3 ± 0.8 years. 35% of the patients complained of vasomotor symptoms before the start of the trial. This rate increased to 60.0% during the first year of the trial, being similar among patients using tamoxifen (57.1%) and toremifene (62.7%). Vaginal dryness, which was present in 6.0% at baseline, increased during the use of tamoxifen (26.2%) and toremifene (24.1%). Endometrial thickness increased from baseline (3.9 ± 2.7 mm) to 6.8 ± 4.2 mm at 6 months (P< 0.001), and no difference emerged between the 2 regimens in this regard. Before the start of the antioestrogen regimen, the endometrium was atrophic in 71 (75.5%) and proliferative in 19 of 94 (20.2%) samples; 4 patients had benign endometrial polyps. During the use of antioestrogen altogether 339 endometrial samples were taken (159 in tamoxifen group, 180 in toremifene group). The endometrium was proliferative more often in the tamoxifen group (47.8%) than in the toremifene group (32.2%) (P< 0.0001). 20 patients had a total of 24 polyps (17 in tamoxifen and 9 in toremifene group, P< 0.05) during the use of antioestrogens. One patient in the toremifene group developed endometrial adenocarcinoma at 12 months, and one patient had breast cancer metastasis on the endometrium. Tamoxifen failed to affect the PI in the uterine artery, but toremifene reduced it by 15.0% (P< 0.05) by 12 months. In conclusion, tamoxifen and toremifene cause similarly vasomotor and vaginal symptoms. Neither regimen led to the development of premalignant endometrial changes. Our data suggest that so close endometrial surveillance as used in our study may not be mandatory during the first 3 years of use of antioestrogen treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: breast cancer, antioestrogens, tamoxifen, toremifene, endometrium

Full Text

The Full Text of this article is available as a PDF (199.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami H. O., Bergström R., Weiderpass E., Persson I., Barlow L., McLaughlin J. K. Risk for endometrial cancer following breast cancer: a prospective study in Sweden. Cancer Causes Control. 1997 Nov;8(6):821–827. doi: 10.1023/a:1018404110180. [DOI] [PubMed] [Google Scholar]
  2. Barakat R. R. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol. 1996 Sep;39(3):629–640. doi: 10.1097/00003081-199609000-00012. [DOI] [PubMed] [Google Scholar]
  3. Buckley M. M., Goa K. L. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 1989 Apr;37(4):451–490. doi: 10.2165/00003495-198937040-00004. [DOI] [PubMed] [Google Scholar]
  4. Cacciatore B., Paakkari I., Toivonen J., Tikkanen M. J., Ylikorkala O. Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow. Obstet Gynecol. 1998 Oct;92(4 Pt 1):563–568. doi: 10.1016/s0029-7844(98)00269-5. [DOI] [PubMed] [Google Scholar]
  5. Chambers J. T., Chambers S. K. Endometrial sampling: When? Where? Why? With what? Clin Obstet Gynecol. 1992 Mar;35(1):28–39. doi: 10.1097/00003081-199203000-00007. [DOI] [PubMed] [Google Scholar]
  6. Cohen I., Altaras M. M., Lew S., Tepper R., Beyth Y., Ben-Baruch G. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol Oncol. 1994 Dec;55(3 Pt 1):443–447. doi: 10.1006/gyno.1994.1319. [DOI] [PubMed] [Google Scholar]
  7. Cohen I., Rosen D. J., Tepper R., Cordoba M., Shapira Y., Altaras M. M., Yigael D., Beyth Y. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993 May;12(5):275–280. doi: 10.7863/jum.1993.12.5.275. [DOI] [PubMed] [Google Scholar]
  8. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994 Apr 6;86(7):527–537. doi: 10.1093/jnci/86.7.527. [DOI] [PubMed] [Google Scholar]
  9. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371–1388. doi: 10.1093/jnci/90.18.1371. [DOI] [PubMed] [Google Scholar]
  10. Fornander T., Hellström A. C., Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 1993 Nov 17;85(22):1850–1855. doi: 10.1093/jnci/85.22.1850. [DOI] [PubMed] [Google Scholar]
  11. Friedl A., Jordan V. C. What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat. 1994;31(1):27–39. doi: 10.1007/BF00689674. [DOI] [PubMed] [Google Scholar]
  12. Garfinkel L., Boring C. C., Heath C. W., Jr Changing trends. An overview of breast cancer incidence and mortality. Cancer. 1994 Jul 1;74(1 Suppl):222–227. doi: 10.1002/cncr.2820741304. [DOI] [PubMed] [Google Scholar]
  13. Goldstein S. R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1994 Feb;170(2):447–451. doi: 10.1016/s0002-9378(94)70209-8. [DOI] [PubMed] [Google Scholar]
  14. Hayes D. F., Van Zyl J. A., Hacking A., Goedhals L., Bezwoda W. R., Mailliard J. A., Jones S. E., Vogel C. L., Berris R. F., Shemano I. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2556–2566. doi: 10.1200/JCO.1995.13.10.2556. [DOI] [PubMed] [Google Scholar]
  15. Hillard T. C., Bourne T. H., Whitehead M. I., Crayford T. B., Collins W. P., Campbell S. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril. 1992 Nov;58(5):959–963. doi: 10.1016/s0015-0282(16)55442-9. [DOI] [PubMed] [Google Scholar]
  16. Holli K. Adjuvant trials of toremifene vs tamoxifen: the European experience. Oncology (Williston Park) 1998 Mar;12(3 Suppl 5):23–27. [PubMed] [Google Scholar]
  17. Ismail S. M. The effects of tamoxifen on the uterus. Curr Opin Obstet Gynecol. 1996 Feb;8(1):27–31. [PubMed] [Google Scholar]
  18. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318–1321. doi: 10.1016/s0140-6736(94)92466-x. [DOI] [PubMed] [Google Scholar]
  19. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P. J., Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993 May;81(5 ):660–664. [PubMed] [Google Scholar]
  20. Love R. R., Cameron L., Connell B. L., Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991 Sep;151(9):1842–1847. [PubMed] [Google Scholar]
  21. McGonigle K. F., Shaw S. L., Vasilev S. A., Odom-Maryon T., Roy S., Simpson J. F. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol. 1998 Jun;178(6):1145–1150. doi: 10.1016/s0002-9378(98)70315-1. [DOI] [PubMed] [Google Scholar]
  22. Neven P. Endometrial changes in patients on tamoxifen. Lancet. 1995 Nov 11;346(8985):1292–1292. [PubMed] [Google Scholar]
  23. Pirhonen J. P., Vuento M. H., Mäkinen J. I., Salmi T. A. Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. Am J Obstet Gynecol. 1993 Feb;168(2):620–630. doi: 10.1016/0002-9378(93)90506-e. [DOI] [PubMed] [Google Scholar]
  24. Pyrhönen S., Ellmén J., Vuorinen J., Gershanovich M., Tominaga T., Kaufmann M., Hayes D. F. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1999 Jul;56(2):133–143. doi: 10.1023/a:1006250213357. [DOI] [PubMed] [Google Scholar]
  25. Ribeiro G., Swindell R. The Christie hospital adjuvant tamoxifen trial--status at 10 years. Br J Cancer. 1988 Jun;57(6):601–603. doi: 10.1038/bjc.1988.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rutqvist L. E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995 May 3;87(9):645–651. doi: 10.1093/jnci/87.9.645. [DOI] [PubMed] [Google Scholar]
  27. Stewart H. J., Forrest A. P., Everington D., McDonald C. C., Dewar J. A., Hawkins R. A., Prescott R. J., George W. D. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer. 1996 Jul;74(2):297–299. doi: 10.1038/bjc.1996.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tesoro M. R., Borgida A. F., MacLaurin N. A., Asuncion C. M. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol. 1999 Mar;93(3):363–366. doi: 10.1016/s0029-7844(98)00418-9. [DOI] [PubMed] [Google Scholar]
  29. Tomás E., Kauppila A., Blanco G., Apaja-Sarkkinen M., Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol. 1995 Nov;59(2):261–266. doi: 10.1006/gyno.1995.0019. [DOI] [PubMed] [Google Scholar]
  30. Touraine P., Driguez P., Cartier I., Yaneva H., Kuttenn F., Mauvais-Jarvis P. Lack of induction of endometrial hyperplasia with tamoxifen. Lancet. 1995 Jan 28;345(8944):254–255. [PubMed] [Google Scholar]
  31. Widrich T., Bradley L. D., Mitchinson A. R., Collins R. L. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol. 1996 Apr;174(4):1327–1334. doi: 10.1016/s0002-9378(96)70680-4. [DOI] [PubMed] [Google Scholar]
  32. Wiseman L. R., Goa K. L. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs. 1997 Jul;54(1):141–160. doi: 10.2165/00003495-199754010-00014. [DOI] [PubMed] [Google Scholar]
  33. di Salle E., Zaccheo T., Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem. 1990 Jun 22;36(3):203–206. doi: 10.1016/0022-4731(90)90005-d. [DOI] [PubMed] [Google Scholar]
  34. van Leeuwen F. E., Benraadt J., Coebergh J. W., Kiemeney L. A., Gimbrère C. H., Otter R., Schouten L. J., Damhuis R. A., Bontenbal M., Diepenhorst F. W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994 Feb 19;343(8895):448–452. doi: 10.1016/s0140-6736(94)92692-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES